Design and development of vaginal wall mimicking poly( ϵ -caprolactone) based nanofibrous prosthetic mesh for pelvic organ prolapse: evaluation of biocompatibility and antibacterial ability.
Arul Murugan P., Bellare J.
Animal Study, published in Biomed Mater (2025) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Animal Study
- Journal
- Biomed Mater (2025)
- Country
- England
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 39715589
- DOI
- 10.1088/1748-605X/ada2d0
Abstract (original English)
Mechanical non-conformance of conventionally used transvaginal non-degradable meshes has led to complications such as organ perforation, dyspareunia caused by mesh stiffness and stress shielding. In this study, we have solved the dire need to mimic the mechanical properties of the vaginal wall by designing and developing a soft and elastic mesh made of polycaprolactone (PCL), citric acid modified polyethylene glycol (PEGC) and zinc oxide (ZnO) prepared through electrospinning and tested in vitro and in vivo . The mesh containing 90:10:0.1 of PCL, PEGC and ZnO (PEGC-15 0.1ZnO mesh) conforms to the mechanical properties of the vaginal wall of the pelvic floor, has a burst strength of ∼35 N even after gamma-sterilization and 28 d of degradation in in vitro . In vitro studies using adipose-derived stem cells revealed that the PCL-PEGC-15 0.1ZnO meshes were biocompatible and supported higher collagen production than commercial mesh. An in vitro bacterial adhesion study showed a 2-log reduction compared to commercially available mesh for prolapse treatment. Initial biocompatibility assessment in a rabbit model also showed that the PCL-PEGC-15 0.1ZnO mesh is biocompatible and supports fibrosis throughout the mesh. The softness and flexibility of the PCL-PEGC-15 0.1ZnO mesh based on in vitro trials and initial in vivo trials show that the mesh has a potential clinical impact for pelvic
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.